NeuBase Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

NeuBase Therapeutics

23/12/2021 22:06

* NeuBase Therapeutics Inc  NBSE.OQ  reported a quarterly
adjusted loss of 21 cents​​ per share for the quarter ended in
September. The mean expectation of four analysts for the quarter
was for a loss of 23 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* NeuBase Therapeutics Inc's reported EPS for the quarter was a
loss of 21 cents​.
* The mean earnings estimate of analysts was unchanged in the
last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* NeuBase Therapeutics Inc shares had fallen by 19.7% this
quarter and lost 58.5% so far this year.
* The company reported a quarterly loss of $7.16 million.
* Wall Street's median 12-month price target for NeuBase
Therapeutics Inc is $16.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated December 23 at 10:05 p.m.
 ​All figures in US dollars unless otherwise stated